Pacific Biosciences of California, Inc. (PACB) Stock

Pacific Biosciences of California, Inc. (PACB) is a Technology stock trading at $1.23 (as of 2026-08-20), with a market capitalization of $380.77M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pacific Biosciences of California, Inc. develops and manufactures DNA sequencing systems and related consumables used for real-time sequencing workflows. Its offerings include sequencing instruments, SMRT cells, and reagent and kit products for preparing and running assays, serving research institutions, commercial laboratories, genome centers, public health and clinical organizations, and pharmaceutical and agricultural customers.

Understand Pacific Biosciences of California, Inc.: how it makes money

Pacific Biosciences develops and manufactures sequencing systems and related consumables and reagent kits, making money from instrument revenue and repeat consumables sales.

The company’s profit model relies on building an installed base of sequencing systems, so customers buy recurring consumable cells and workflow reagents that generate ongoing revenue.

Revenue by segment (latest quarter)
Instruments$0.0B
Consumables$0.0B

Business quality (Weak): Useful operational signals are available for the Revio platform (system shipments and installed base), but reported total revenue is extremely small/rounded, which makes quarter to quarter interpretation more difficult.

Bull case

  • Revio platform momentum: During the quarter, the company reports 44.0 Revio Sequencing Systems Shipped for Revenue, with an Ending Installed Base of 200.0 systems.
  • Recurring revenue potential from consumables: The business includes consumables and workflow reagents (such as SMRT cells and specific reagent kits), which can support repeat purchasing tied to an installed base.

Bear case

  • Quarterly revenue visibility is limited: Total reported revenue is 0.0B for the latest period shown, so performance signals may be harder to interpret from quarter to quarter.
  • Operating losses: The company reports an operating margin of -22.5%, indicating costs exceed operating profit in the latest period.
  • Pull through may not yet scale: The reported Annualized Consumable Pull Through on the Revio Platform is 0.0, suggesting consumables monetization may not be established at this point or may not yet be reflected in the reported metric.
Valuation — source: SEC EDGAR (first-party)
Price$1.23
Market Cap$380.77M
Price / Sales2.39
FCF Yield-32.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$160.00M
Net Margin-341.5%
Revenue Growth (YoY)-1.9%
EPS Growth (YoY)0.0%
FCF Growth (YoY)24.1%
Financial Health — source: SEC EDGAR
Altman Z-Score-6.19 (distress)
Valuation vs Sector & Industry
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderARK Investment Management LLC ($47.88M)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEOChristian O. Henry
Employees575
CountryUS
IPO Date2010-10-27

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Alamar Biosciences, Inc. (ALMR)
  • Cytek Biosciences, Inc. (CTKB)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • Harvard Bioscience, Inc. (HBIO)
  • Quanterix Corporation (QTRX)
  • Nautilus Biotechnology, Inc. (NAUT)
  • Seer, Inc. (SEER)
  • Rapid Micro Biosystems, Inc. (RPID)
PACB earnings history · PACB institutional & insider holders · PACB KPIs & operating metrics · PACB financials · PACB investor presentations & press releases · PACB SEC filings · PACB peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.